Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Thibault Fiolet, Anthony Guihur, Mathieu Edouard Rebeaud, Matthieu Mulot, Nathan Peiffer-Smadja, Yahya Mahamat-Saleh
Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.08.022
Background: Hydroxychloroquine or chloroquine with or without azithromycin have been widely promoted to treat coronavirus disease 2019 (COVID-19) following early in vitro antiviral effects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objective: The aim of this systematic review and meta-analysis was to assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased COVID-19 mortality compared with the standard of care.
Transparency declaration All authors declare no support from any organization for the submitted work other than that described above; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; and no other relationships or activities that could appear to have influenced the submitted work.
Authors' contributions TF designed the research. TF, MR, AG, MM, NPS and YMS conducted the research. TF performed the statistical analysis and wrote the first draft of the paper. MR, AG, MM, NPS and YMS contributed to the writing of the paper. All authors contributed to the data interpretation, revised each draft for important intellectual content, and read and approved the final manuscript.
Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2020.08.022.
References
Alberici, Delbarba, Manenti, Econimo, Valerio et al., A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection, Kidney Int,
doi:10.1016/j.kint.2020.04.030Alexander, Debono, Mammen, Iorio, Aryal et al., COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2020.04.016Andreani, Bideau, Duflot, Jardot, Rolland et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis
Ayerbe, Risco, Ayis, The association between treatment with heparin and survival in patients with Covid-19, J Thromb Thrombolysis,
doi:10.1007/s11239-020-02162-zBalduzzi, Rücker, Schwarzer, How to perform a meta-analysis with R: a practical tutorial, Evid Based Ment Health
Barbosa, Kaitis, Freedman, Le, Lin, Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative study
Begg, Mazumdar, Operating characteristics of a rank correlation test for publication bias, Biometrics
Bessi Ere, Roccia, Delini Ere, Charri Ere R, Chevalier et al., Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit, JAMA Cardiol,
doi:10.1001/jamacardio.2020.1787Borba, Val, Sampaio, Alexandre, Melo et al., Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial, JAMA Netw Open
Bousquet, Falgarone, Deutsch, Derolez, Lopez-Sublet et al., ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with COVID-19, Aging
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2019014Chorin, Wadhwani, Magnani, Dai, Shulman et al., QT interval prolongation and Torsade De Pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin, Heart Rhythm,
doi:10.1016/j.hrthm.2020.05.014Commissioner, The, Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine
Cravedi, Suraj, Azzi, Haverly, Farouk et al., COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium, Am J Transplant n.D,
doi:10.1111/ajt.16185Dersimonian, Laird, Meta-analysis in clinical trials, Control Clin Trial
Dimitrova, COVID-19: reminder of risk serious side effects with chloroquine and hydroxychloroquine
Docherty, Harrison, Green, Hardwick, Pius et al., Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ
Dyall, Gross, Kindrachuk, Johnson, Olinger et al., Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies, Drugs
Fontana, Alfano, Mori, Amurri, Tei et al., COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine, Am J Transplant
Fontana, Giaroni, Frisina, Alfano, Mori et al., SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience, Clin Kidney J
Fragkou, Belhadi, Peiffer-Smadja, Moschopoulos, Lescure et al., Review of trials currently testing treatment and prevention of COVID-19, Clin Microbiol Infect
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2012410Gupta, Hayek, Chan, Mathews, Melamed, Factors associated with death in critically ill patients with coronavirus disease 2019 in the USA, JAMA Intern Med,
doi:10.1001/jamainternmed.2020.3596Guyatt, Oxman, Vist, Kunz, Brozek et al., GRADE guidelines: 4. Rating the quality of evidencedstudy limitations (risk of bias), J Clin Epidemiol
Hernandez, Roman, Pasupuleti, Barboza, White, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review, Ann Intern Med,
doi:10.7326/M20-2496Higgins, Thompson, Quantifying heterogeneity in a meta-analysis, Stat Med
Higgins, Thompson, Spiegelhalter, A re-evaluation of random-effects meta-analysis, J R Stat Soc Ser A Stat Soc
Hill, Wang, Levi, Heath, Fortunak, Minimum costs to manufacture new treatments for COVID-19, J Virus Erad
Hopewell, Mcdonald, Clarke, Egger, Grey literature in meta-analyses of randomized trials of health care interventions, Cochrane Database Syst Rev,
doi:10.1002/14651858.MR000010.pub3Horby, Mafham, Linsell, Bell, Staplin et al., Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial, MedRxiv,
doi:10.1101/2020.07.15.20151852Huang, Li, Xiao, Pang, Liang et al., Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19, Natl Sci Rev n,
doi:10.1093/nsr/nwaa113Ip, Berry, Hansen, Goy, Pecora et al., Hydroxychloroquine and tocilizumab therapy in COVID-19 patientsdan observational study, Infectious Diseases,
doi:10.1101/2020.05.21.20109207Jun, Jun, A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19, J Zhejiang Univ (Med Sci
Khamis, Al-Zakwani, Naamani, Lawati, Pandak et al., Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: an experience from Oman, J Infect Public Health,
doi:10.1016/j.jiph.2020.06.002Kuderer, Choueiri, Shah, Shyr, Rubinstein et al., Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, Lancet,
doi:10.1016/S0140-6736(20)31187-9Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101791Lane, Weaver, Kostka, Duarte-Salles, Abrahao et al., Safety of hydroxychloroquine, alone and in combination with azithromycin,
doi:10.1101/2020.04.08.20054551Lecronier, Beurton, Burrel, Haudebourg, Deleris et al., Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis, Crit Care
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19, Med,
doi:10.1016/j.medj.2020.06.001Mah Evas, Tran, Roumier, Chabrol, Paule et al., Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ,
doi:10.1136/bmj.m1844Maisonnasse, Guedj, Contreras, Behillil, Solas et al., Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates, Nature,
doi:10.1038/s41586-020-2558-4Maisonnasse, Guedj, Contreras, Behillil, Solas et al., Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates, Nature
Mallat, Hamed, Balkis, Mohamed, Mooty et al., Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: a retrospective study, MedRxiv,
doi:10.1101/2020.04.27.20082180Mcauley, Pham, Tugwell, Moher, Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?, Lancet
Mcguinness, Higgins, Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments, Res Synth Methods,
doi:10.1002/jrsm.1411Mdaa, Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases, Pharmacol Res Perspect
Membrillo, Ramírez-Olivencia, Est Ebanez, De, Herrero et al., Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study,
doi:10.20944/preprints202005.0057.v2Mercuro, Yen, Shim, Maher, Mccoy et al., Risk of QT Interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19), JAMA Cardiol,
doi:10.1001/jamacardio.2020.1834Mikami, Miyashita, Yamada, Harrington, Steinberg et al., Risk factors for mortality in patients with COVID-19 in New York City, J Gen Intern Med,
doi:10.1007/s11606-020-05983-zNguyen, Dolladille, Drici, Fenioux, Alexandre et al., Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the world health organization pharmacovigilance database, Circulation
Paccoud, Tubach, Baptiste, Bleibtreu, Hajage et al., Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe COVID-19 in a French university hospital, Clin Infect Dis n,
doi:10.1093/cid/ciaa791Patel, Barvaliya, Kevadiya, Patel, Bhalla, Does adding of hydroxychloroquine to the standard care provide any benefit in reducing the mortality among COVID-19 patients?: a systematic review, J Neuroimmune Pharmacol,
doi:10.1007/s11481-020-09930-xPeiffer-Smadja, Lescure, Sallard, Ravaud, Vegreville et al., Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19, J Antimicrob Chemother n,
doi:10.1093/jac/dkaa223Rivera, Peters, Panagiotou, Shah, Kuderer et al., Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study, Cancer Discov,
doi:10.1158/2159-8290.CD-20-0941Rogado, Obispo, Pangua, Serrano-Montero, Marino et al., Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid, Clin Transl Oncol,
doi:10.1007/s12094-020-02381-zRosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with inhospital mortality in patients with COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630S Anchez-Alvarez, Font An, Mp, Martín, Pelícano et al., Status of SARS-CoV-2 infection in patients on renal replacement therapy,
doi:10.1016/j.nefroe.2020.04.002Saleh, Gabriels, Chang, Kim, Mansoor et al., The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection, Circ Arrhythm Electrophysiol,
doi:10.1161/CIRCEP.120.008662Sarma, Kaur, Kumar, Mahendru, Avti et al., Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis, J Med Virol
Sbidian, Josse, Lemaitre, Mayer, Bernaux et al., Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France,
doi:10.1101/2020.06.16.20132597Singh, Khan, Chowdhry, Chatterjee, Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United Statesdrealworld evidence from a federated electronic medical record network, Infect Dis (except HIV/AIDS,
doi:10.1101/2020.05.12.20099028Singh, Singh, Singh, Misra, Hydroxychloroquine in patients with COVID-19: a systematic review and meta-analysis, Diabetes Metab Syndr
Skipper, Pastick, Engen, Bangdiwala, Abassi et al., Hydroxychloroquine in nonhospitalized adults with early COVID-19, Ann Intern Med,
doi:10.7326/M20-4207Sterne, Hern An, Reeves, Savovi C, Berkman et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ
Sterne, Savovi C, Page, Elbers, Blencowe et al., RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ,
doi:10.1136/bmj.m1849Training, Cochrane handbook for systematic reviews of interventions
Viechtbauer, Cheung, Outlier and influence diagnostics for metaanalysis, Res Synth Method
Wang, Zhong, Hurd, Comorbidity and sociodemographic determinants in COVID-19 mortality in a US urban healthcare system, Infectious Diseases,
doi:10.1101/2020.06.11.20128926Wilkinson, RECOVERY trial: the UK COVID-19 study resetting expectations for clinical trials, BMJ,
doi:10.1136/bmj.m1626Yao, Ye, Zhang, Cui, Huang et al., Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis n,
doi:10.1093/cid/ciaa237Yu, Li, Chen, Zhou, Wang et al., Low dose of hydroxychloroquine reduces fatality of critically ill patients with, Sci China Life Sci
